Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic Prucalopride Tablets in 1 mg and 2 mg strengths.
The medicine is approved for treating chronic idiopathic constipation in adults and is therapeutically equivalent to Takeda Pharmaceuticals USA’s Motegrity tablets. The approval allows Alembic to introduce a more affordable generic alternative in the United States market.
The US market for Prucalopride Tablets is estimated at around ₹940 crore, or US$100 million, offering a significant commercial opportunity for the company.
The approval expands Alembic’s portfolio of USFDA-approved medicines and strengthens its presence in regulated international markets. It also highlights the growing role of Indian pharmaceutical companies in supplying affordable, quality-assured generic medicines worldwide.
You may also like
-
Indian MedTech Startup Periwinkle Takes Rapid AI Cervical Cancer Screening to BRICS
-
WHO Chief Praises India’s Gains in Maternal, Child Health and NCD Care
-
Ayurvedic Foods for Liver Health and Digestion
-
Ayurvedic Diet for Joint Health and Stiffness
-
Ayurvedic Breakfasts: What Traditional Ayurveda Suggests for the First Meal of the Day
